Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1989 Jun:8 Suppl 2:48-51.
doi: 10.1007/BF02207233.

Endocrine aspects of menopause

Affiliations
Review

Endocrine aspects of menopause

A G Vagenakis. Clin Rheumatol. 1989 Jun.

Abstract

Oocyte depletion and ovarian aging results in profound alterations at the biological level. The reduction in numbers of follicles leads to reduction of circulating inhibin and increased serum FSH, characteristic marker of ovarian failure. The remaining follicles are overstimulated and premature ovulation may ensue. This, leads to luteal deficiency and reduction in progesterone production and relative hyperestrogenemia. The above changes characterize the premenopausal period. In a second phase, anovulatory cycles interchange with premature and occasionally normal ovulatory cycles. This phase is characterized by increased FSH and LH and decreased progesterone/estradiol ratio resulting in irregular bleeding, endometrial hyperplasia, polyps, fibromas, mammary dystrophies, disturbance of mood, appetite and thermoregulation. Lastly, the sensitivity of ovarian follicles to FSH and LH is lost with a decline of E2 below 20 pg/ml produced almost exclusively from peripheral conversion from circulating androgens. The beneficial effects of E2 are lost resulting in atrophy of the sensitive tissues, decreased calcium absorption, increased bone resorption, accelerated bone loss and osteoporosis, rise in serum triglycerides, increased VLDL and LDL lipoproteins, increased LDL/HDL cholesterol, a profile which favors atherosclerosis.

PubMed Disclaimer

References

    1. J Clin Endocrinol Metab. 1972 Apr;34(4):671-5 - PubMed
    1. J Clin Endocrinol Metab. 1979 Jul;49(1):152-4 - PubMed
    1. Rev Fr Gynecol Obstet. 1985 Mar;80(4):187-90 - PubMed
    1. J Clin Endocrinol Metab. 1973 Feb;36(2):207-14 - PubMed
    1. J Appl Physiol. 1975 Mar;38(3):499-503 - PubMed

LinkOut - more resources